CD7 Proteïne (C-His, mens)

CD7

GP40, LEU-9, Tp40, TP41

C-His

< 1.0 EU per μg protein as determined by the LAL method.

1.Flow cytometric analysis of anti-CD7 CAR expression. 5e5 of anti-CD7 CAR-293 cells were stained with 100 μL of 1 μg/mL of AF 647-conjugated human CD7 Protein (Site-Specific AF 647 Conjugation, ECD, His Tag, Cat. No. 11028-H86H-SG) and negative control protein. Non-transduced 293 cells were used as a control (left) . AF 647 signal was used to evaluate the binding activity (QC tested) . 2.Binding activity of AF 647-conjugated CD7 protein to PBMC cells. PBMC cells were stained with FITC conjugated anti-CD3 antibody and AF 647-conjugated human CD7 Protein (Site-Specific AF 647 Conjugation, ECD, His Tag, Cat. No. 11028-H86H-SG) and detected by flow cytometry. FITC signal was used to evaluate the content of CD3+ T cells in PBMCs. AF 647 signal was used to evaluate the non-specific binding activity to PBMCs (QC tested) . 3.1E5 of mouse Anti-CD7 antibody-conjugated beads (6-8 μm) were stained with a series of concentrations of AF 647-conjugated human CD7 Protein (Site-Specific AF 647 Conjugation, ECD, His Tag, Cat. No. 11028-H86H-SG) . Binding activity was quantified based on AF 647 fluorescence. The recommended working concentration is 0.5 μg/mL (end-user titration is recommended for optimal performance) .

Met 1-Pro 180

The protein has a predicted molecular mass of 19.9 kDa.

Human